Drug formulations under price control rise to over 800

Under NLEM 2011, there were 628 drug formulations that were under the price control which now has been increased to over 800

Image via Shutterstock
<a href="http://www.shutterstock.com/pic-141058420.html" target="_blank">Image</a> via Shutterstock
Press Trust of India New Delhi
Last Updated : Mar 13 2016 | 12:37 PM IST
The government has increased the number of drugs under price control to over 800 formulations, bringing medicines used for treatment of diseases such as cancer, HIV/AIDS, analgesics and cardiovascular diseases under its purview.

Officially confirming addition of over 200 formulations under price cap, the Department of Pharmaceuticals has notified amendment of the Schedule I of Drug Price Control Order (DPCO) 2013 for substituting the National List of Essential Medicines (NLEM) 2011 by NLEM 2015.

"Earlier 628 drug formulations were under price control under NLEM 2011, now it has been increased to over 800," a senior official told PTI.

Also Read

When asked for comment on its implications on the pharma sector, Indian Pharmaceutical Alliance Secretary General D G Shah said: "The exact impact on the industry will be known only when the average ceiling price on these drugs, which have been brought under the control, is decided by NPPA."

The process of fixing the ceiling prices could take another two months, the official said.

In December 2015, a core committee constituted by the Health Ministry had added 106 medicines while 70 were deleted in a revision of the NLEM 2011 and expanding the list of national list of essential medicines to 376 from 348.

The 106 drugs added to the national list of essential medicines included that for Cancer, HIV/AIDS, cardiology and Hepatitis C among others.

A variety of drug formulations are derived from these essential medicines, which satisfy the priority healthcare needs of the population and are listed with reference to the various levels of healthcare namely primary, secondary and tertiary.

The National Pharmaceutical Pricing Authority (NPPA) is mandated to fix or revise prices of controlled bulk drugs, formulations and to enforce prices and availability of the medicines in the country besides monitoring prices of decontrolled drugs in order to keep them at reasonable levels.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 13 2016 | 12:02 PM IST

Next Story